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Summary The Differential Staining Cytotoxicity (DiSC) assay has been used to study the effects of sample
source and cell concentration on the in vitro chemosensitivity of haematological malignancies.
The chemosensitivity of blood and bone marrow samples was significantly associated (P<0.001) in 12 cases
where both were tested simultaneously. In 8 of the cases, where the in vitro result could be compared with
clinical response, the in vitro and in vivo chemosensitivity was in agreement in 7, for both blood and bone
marrow samples.
The in vitro chemosensitivity of chronic lymphocytic leukaemia blood lymphocytes was dependent on the
cell concentration for 4 out of 5 drugs tested. A five fold reduction in cell number resulted in a significantly
greater cell kill with 4-hydroperoxycyclophosphamide, a greater cell kill (not significant) with chlorambucil
and adriamycin, and a significantly lower cell kill with prednisolone. The cell concentration did not affect
vincristine cytotoxicity.
These results suggest that sample source is not an important consideration for the in vitro chemosensitivity
of leukaemias, but that the cell concentration tested should not be varied from assay to assay if the results are
to be used for comparative purposes.
In vitro chemosensitivity tests have proved to be of
use for predicting tumour response in vivo (Hill,
1983). However, there are always a small
proportion of discrepancies between the in vitro and
in vivo results. Besides pharmacokinetic differences
between the in vitro and in vivo situations, these
discrepancies may be due to heterogeneous chemo-
sensitivity of tumour cells in different sites within
one particular tumour-bearing individual, so that
sampling from one site may not reflect the overall
clinical response of the patient. Such heterogeneity
has been shown for solid tumours, both within a
primary tumour, and between a primary tumour
and its metastases (Schlag & Schreml, 1982; Kern et
al., 1984; San Filippo et al., 1984; Von Hoff &
Clark, 1984). The chemosensitivity of tumour cells
taken from different biopsy sites in haematological
tumours has, however, not been similarly
investigated. We have, therefore, studied the
chemosensitivity of leukocytes taken simultaneously
from peripheral blood and bone marrow of patients
with chronic lymphocytic leukaemia (CLL), acute
lymphoblastic leukaemia (ALL) and acute myeloid
leukaemia (AML), using a short-term differential
staining cytotoxicity (DiSC) assay previously
reported by us and others (Bird et al., 1985, 1986;
Bosanquet et al., 1983; Weisenthal et al., 1984).
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It has been postulated that cell destruction by
anticancer drugs follow 'first order kinetics' (Hill,
1978), and that a given treatment destroys a
constant fraction of cells, not a fixed number. It
follows from this 'fractional kill' hypothesis that
cell kill should be independent of cell number for
any given concentration of drug. Although this
hypothesis holds good for certain exponentially-
growing experimental tumours (such as the L1210
leukaemia), it is less satisfactory for most
experimental and clinical tumours which seem to
more closely follow Gompertzian growth kinetics
(Norton & Simon, 1977). Thus there have been
reports that, for some agents, cytotoxicity in vitro is
profoundly affected by the ratio of cell
concentration to drug dose, both in established cell
lines (Chambers et al., 1984; Arkin et al., 1984) and
in primary cultures (K6rbling et al., 1982; Herve et
al., 1983). For this reason we have also examined
the relationship between cell concentration and cell
kill in the DiSC assay for five different drugs, using
peripheral blood lymphocytes from CLL patients.
Materials and methods
Samples and cell separation
For comparison of blood and bone marrow
leukocyte chemosensitivity, a bone marrow aspirate
and a peripheral blood sample were collected from
12 patients and processed simultaneously. Six
patients had ALL, 3 had AML and 3 had CLL. All
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the samples were taken at diagnosis (therefore no
previous chemotherapy) except for one patient with
CLL (patient 6 in Table I). This person had been
diagnosed 6 years earlier and received chemo-
therapy, although in the 6 months prior to the
samples being taken he had only received one 4-day
course of chlorambucil and prednisolone. Although
more pairs of samples were collected, only those
showing > 10% tumour cells in both samples could
be analysed by the DiSC assay.
For the cell concentration experiments, blood
samples were collected from 9 CLL patients who, if
they had had chemotherapy, had not received it in
the previous three weeks.
Peripheral blood samples (5-10ml) were collected
into potassium EDTA tubes and bone marrow
(0.2-1.0ml) into lithium heparin tubes. Samples
were diluted 1:1 (v/v) with PBS, and the leukocyte
population (always >98% viable) was obtained by
centrifugation over Ficoll-hypaque as described
previously (Bird et al., 1985).
DiSC assay
Drugs were made up and stored in the most
appropriate media as described elsewhere (Bird et
al., 1986). The DiSC or micro-DiSC assay was
performed as previously described (Bird et al., 1985,
1986). Briefly, drugs were diluted to the required
concentration range with PBS, and incubated with
cells (lxl05ml-1 or 5x105 ml-1 in RPMI 1640
medium containing 10% foetal calf serum and
24mM NaHCO3 (RPMI-FCS)) under 5% CO2 at
37°C for4days. Single tubes were set upforeachdrug
concentration and six control tubes received PBS in
place of the drug. (With this system, the standard
deviation on the results has been variously estimated
at 12% and 20% (Bird et al., 1985, 1986)). Following
this, cells were stained with nigrosin-fast green stain,
containing a known number of permanently fixed
duck red blood cells (DRBC), and cytocentrifuged
onto collagen-coated slides. The slides were then fixed
with methanol, and counterstained with a
Romanowsky stain. For quantification ofresults, the
ratio oflive tumour cells over simultaneously counted
DRBC was determined for each slide and the ratio in
drug-treated samplesexpressed as apercentage ofthat
in the control. This expression was termed the tumour
cell survival (TCS).
Statistical analysis
Paired t-tests and calculation of correlation
coefficients were performed by using the statistical
package, Minitab (Ryan et al., 1981), on a
Honeywell Series 60 mainframe computer.
Results
Blood and bone marrow chemosensitivity
Leukocytes from 12 pairs of bone marrow aspirates
and peripheral blood samples (6 ALL, 3 AML and
3 CLL) obtained simultaneously were assayed by
the DiSC or micro-DiSC assay. The control
viability of blood samples at the end of the 4-day
assay was significantly higher than those of marrow
leukocytes (P<0.05; paired t-test) with means of
55% and 45% for the two sample sources over the
12 patients studied. A total of 250 drug
comparisons were possible for the 12 patients. The
TCS values obtained in the assay for the two
sample sources were plotted against each other and
the results are shown in Figure 1. Overall the data
was very well correlated (r=0.69; P<<0.001) and
the best fit line (shown in Figure la) lay close to
x=y. This relationship remained when the TCS
values for ALL and AML patients were plotted
separately (Figure lb and c). For the 3 CLL
patients the data was also well correlated
(P<<0.001) around the best fit line (Figure ld), but
there was significant deviation from x=y, with the
TCS values for marrow being generally higher than
those for blood leykocytes (paired t test; P<0.01).
For further analysis all the TCS values in Figure
1 were assigned as being sensitive (_30% TCS) or
resistant (>30% TCS). Differences in sensitivity of
blood and bone marrow by these criteria were
found in 28 of the 250 possible comparisons (11%),
comprising 5 (9%) of the CLL comparisons, 3 (6%)
of the AML comparisons, and 20 (16%) of the
ALL comparisons.
To determine if the category of antineoplastic
agent made any difference in the correlation
between sensitivity or resistance in blood and bone
marrow cells, the mean dose response curves for the
three most studied drugs (prednisolone (Pred),
daunorubicin (Dnr) and vincristine (Vc)) in blood
and bone marrow samples were plotted (Figure 2).
The differences between the TCS values were far
from significant for the two sample sources (paired
t-test; P>0.2, 0.6 and 0.7 for Pred, Vc and Dnr
respectively) and the overall shape of the curves
were very similar with the area under the dose-
response curve (AUC) for each of the mean curves
(shown in Figure 2) being in good agreement. In 8
cases where the in vitro results could be compared
with clinical response, blood and bone marrow
samples were equally accurate in predicting
response in vivo, giving one false correlation each
(Table I).
Effect ofcell concentration on chemosensitivity
To determine the effects of cell concentration on in
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Figure 1 Comparison of in vitro drug sensitivity in blood and bone marrow leukocytes. Each point
represents a paired TCS value. The line shown is the line of best fit. (a) Total data, r=0.69 (b) ALL, r=0.72
(c) AML, r=0.80 (d) CLL, r=0.53.
patients were tested at two different cell
concentrations (1 x 105 and 5 x 105 viable cells
ml-') for sensitivity to Vc, Pred, 4-hydroperoxy-
cyclophosphamide (4-HC), adriamycin (Adr) and
chlorambucil (Chl) in the DiSC assay. The control
viability of the cells in the assay at 4 days was
significantly greater at the higher seeding density
(paired t-test, P<0.001; mean viability 69% and
46% for 5 x 105 and 1 x l05 cells ml-1 respectively).
The TCS values obtained at the two cell
concentrations were not significantly different for
Vc (paired t-test, P>0.6). For Chl and Adr the
differences in cytotoxicity were not great (paired t-
test, 0.05<P<0.1). This is reflected in quite similar
mean dose response curves for these three drugs in
the 9 patients studied (Figure 3a,b,c). TCS values
for Pred were significantly higher at 1 x 105 cells
ml- 1 than at 5 x 105 ml-1, for all concentrations of
drug tested (paired t-test P<0.01). The overall
shape of the mean dose response curves was similar
at both cell concentrations (Figure 3d). For 4-HC
the TCS values were significantly lower at 1 x 105
cells ml-' than at 5 x 105 ml-1 (overall P<0.05)
with the greatest differences being at the higher
drug concentrations tested (mean differences 3% at
lOOngml-l but 43% at lOOOngml-1). The mean
dose response curve for the 9 patients was steeper
for 1 x 105 cells ml-' (Figure 3e), resulting in a
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Figure 2 Comparison of the mean TCS values in
blood (A) and bone marrow (A) leukocytes for the
three most studied drugs. Each point represents the
mean of TCS values in 7 or more patients, except for
Pred (2000ngml-1) where only 4 patients were
evaluable. (a) Prednisolone (b) Daunorubicin (c)
Vincristine.
Table 1 Comparison of results of the in vitro assay with in vivo response
In vivo/In vitro
In vitro resulta associationb
Type of Bone Bone
Patient neoplasm In vivo result Blood marrow Blood marrow
11 a' CLL NRd with Chl+Pred R Chl, Pred R Chl, Pred R/R R/R
b NR with Cy+Vc+Pred R 4-HC, Vc, S Vc; R 4-HC, R/R R/S
Pred Pred
15 CLL NR with Pred R Pred R Pred R/R R/R
20 ALL CR induced with R Pred, Asp, Vc S Pred, Asp; S/R S/S
Pred+Asp+Vc R Vc
21 ALL CR induced with S Pred; R Dnr, S Pred; R Dnr, S/S S/S
Dnr+Vc+Asp+Pred Asp, Vc Asp, Vc
24 ALL Remission not induced R Dnr, Vc, Asp, R Dnr, Vc, R/R R/R
with Dnr+Vc+Asp Pred Asp, Pred
+Pred
31 ALL CR induced with S Pred, Asp; S Pred, Asp, Vc; S/S S/S
Dnr+Vc+Asp+Pred R Dnr, Vc RDnr
32 ALL CR induced with S Asp, Pred, Dnr; S Dnr, Asp, S/S S/S
Dnr+Vc+Asp+Pred R Vc Pred, Vc
aBased on a sensitive (S)/resistant (R) cut-off point of 30% TCS; bAccording to the criteria of Von Hoff et al. (1981); CPatient numbers continue from Bird et al. (1985); dAbbreviations: CR, complete remission; NR, no response; Dnr,
daunorubicin; Vc, vincristine; Asp, asparaginase; Pred, prednisolone; Chl, chlorambucil; Cy, cyclophosphamide; 4-HC,
4-hydroperoxycyclophosphamide (used in vitro in place ofCy because ofthe inactivity ofCy in vitro).
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Figure 3 Effect of cell concentration on in vitro chemosensitivity. CLL lymphocytes were exposed to the
drugs shown in the DiSC assay at 1 x 105 cellsml- (A) and 5 x I05 cellsml-
' (A). Each point represents the
mean TCS value at each concentration for the 9 patients studied. (a) Vincristine. (b) Chlorambucil. (c)
AdrAamycin. (d) Prednisolone. (e) 4-Hydroperoxycyclophosphamide.
smaller mean AUC (39.6% and 63.8% for 1 x 105
and 5 x l05 cells ml- respectively) at the lower cell
concentration.
Discussion
This study was designed to compare the in vitro
drug sensitivity results obtained from bone marrow
tumour cells with those of circulating tumour cells
in peripheral blood in human leukaemia, and to
determine the effects of cell concentration on the in
vitro chemosensitivity of leukaemic cells. The assay
we have used for this study is a differential staining
cytotoxicity (DiSC or micro-DiSC) assay previously
reported by us and others (Bird et al., 1985, 1986;
Bosanquet et al., 1983; Weisenthal et al., 1984).
This assay has been shown to be reproducible for
repeat samples from the same patient in
haematological tumours (Bird et al., 1985, 1986)
and is, therefore, a good tool for the assessment of
heterogeneity in the in vitro chemosensitivity of
leukaemic cells.
In the acute leukaemias we have studied there
was reasonable homogeneity in the chemosensitivity
of tumour cells in the bone marrow and peripheral
blood. In CLL patients marrow leukocytes gave
higher overall TCS values than peripheral blood
cells. However, this was mainly due to an apparent
growth stimulation of marrow cells at low drug
concentrations, rather than a decrease in drug
sensitivity. Thus when TCS values were assigned as
sensitive (. 30% TCS) or resistant (>30% TCS)
only 5 out of a possible 55 comparisons were
discordant. Using these criteria for sensitivity and
resistance the overall agreement of drug sensitivity
and resistance in bone marrow and blood was very
good with 222 of the 250 comparisons (89%) being
concordant. In contrast Kern et al., (1984) found
concordance in only 227 of 347 comparisons (65%)
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of response to chemotherapy in biopsies of solid
tumours taken from different sites within a patient,
using a 50% cut off point for sensitivity and
resistance. This suggests much greater heterogeneity
of tumour chemosensitivity between primary solid
tumours and their metastases, than between biopsy
sites in the more disseminated leukaemias.
Von Hoff and Clark (1984) found good
correlation between chemosensitivity of a primary
tumour and its metastases for intercalating agents,
but major discordances in chemosensitivity for the
vinca alkaloids. This was not the case in this study
for bone marrow and blood cell chemosensitivity,
with vincristine and daunorubicin both showing
little difference in chemosensitivity between the two
sample sources.
The clinical response of the patient could be
compared with the in vitro chemosensitivity in 8
cases where blood and bone marrow chemo-
sensitivity was determined. For both sample sources
there was a good agreement between clinical
response, or lack of response, and the in vitro
sensitivity data. Although numbers are small, this
would indicate that samples from either source are
probably equally good for predicting in vivo tumour
response. In practice we correlate response with
results from bone marrow for ALL and from blood
samples for CLL.
To determine the effects of cell concentration on
in vitro drug sensitivity, lymphocytes from CLL
patients were tested at two different cell concen-
trations encompassing the range commonly used by
ourselves and others in predicting in vivo response
(Bird et al., 1985; Durie, 1984; Ozols et al., 1984).
The cell kill obtained in the DiSC assay for Vc was
independent of cell density, satisfying the 'fractional
kill' hypothesis. For Chl and Adr, cell kill was
generally slightly higher at 1 x 105 cells ml-' than
at 5 x 105 cells ml-l. For Adr this result contrasts
with the much greater effect seen by Chambers et
al., (1984) who found that a 4-fold increase in cell
density resulted in a 10-fold higher surviving
fraction when using an exponentially-growing
monolayer culture system.
The cell kill observed with 4-HC was significantly
less at 5 x 105 cells ml-l than at 1 x 105 cells ml-1.
This result is in both qualitative and quantitative
agreement with that of Korbling et al., (1982) who
found that the AUC for 4-HC in granulocyte-
macrophage progenitor cells (CFU-c) approxi-
mately doubled with a 10 to 20-fold increase in cell
concentration.
Perhaps the most surprising finding in this study
was that the cell kill caused by the glucocorticoid
hormone, prenisolone, was significantly higher at
5 x 0 1 cellsml-1 than at 1 x 105 cellsml-1. The
reasons for this are unclear, and require further
investigation. Holbrook et al. (1984) found that
CLL lymphocytes produced an endogenous factor
which stabilised the glucocorticoid-receptor
complexes formed in non-lymphocytic leukaemia
cells when the two cell types were mixed, and it is,
therefore, possible that at the lower cell
concentration tested here the steroid-receptor
complex was more labile, resulting in lower cell kill.
The results of this study suggest that the
Gompertzian cell kill model proposed by Norton
and Simon (1977) may be more appropriate to
describe chemosensitivity in CLL than the
fractional kill model developed by Skipper and co-
workers (1964).
An assessment of the factors affecting drug
sensitivity in vitro is of great importance to the
significance of the predictive in vitro tests that have
been developed in recent years to assess the
response of an individual's tumour to chemo-
therapeutic drugs. If such an in vitro test is to be of
use for individual treatment planning the results of
testing must, as far as possible, be unequivocal, and
independent of the biopsy source. For the DiSC
assay of haematological malignancies we have
shown that both peripheral blood and bone
marrow samples may be used to predict clinical
response, making this assay of practical value for
clinical use. For some drugs in vitro chemo-
sensitivity is dependent on the cell concentration
tested, and this variable needs to be carefully
controlled if the results of in vitro assays are to be
used for the prediction of clinical response on a
routine basis.
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